Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
2.040
+0.170 (9.09%)
At close: Nov 9, 2026, 4:00 PM EST
2.050
+0.010 (0.49%)
Pre-market: Nov 10, 2026, 4:59 AM EST

Foghorn Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
112.1330.9122.634.1619.231.32
Revenue Growth
357.33%36.75%-33.83%77.63%1357.77%206.74%
Gross Profit
34.47-54.56-71.93-75.53-86.39-79.01
Operating Income
8.94-82.11-100.29-107.91-117.14-100.73
Net Income
9.42-74.28-86.62-98.43-108.88-101.32
Earnings Per Share
0.13-1.18-1.58-2.34-2.62-2.73
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
156.22158.89243.75234.06345.8154.29
Total Debt
43.8741.2737.1345.0751.5158.33
Net Cash (Debt)
112.35117.62206.62188.98294.2995.96
Net Cash Growth
-28.78%-43.07%9.33%-35.78%206.69%-7.53%
Net Cash Per Share
1.621.873.764.507.082.58

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-83.62-86.1-100.41-118.11193.61-50.25
Capital Expenditures
-0.06-0.05-0.91-1.22-1.21-3.31
Free Cash Flow
-83.68-86.15-101.31-119.33192.4-53.56
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
30.74%-176.51%--221.15%--
Operating Margin
7.97%-265.64%-443.70%-315.93%-609.20%-7637.15%
Pretax Margin
8.40%-240.33%-383.24%-275.80%-566.27%-7681.58%
Profit Margin
8.40%-240.33%-383.24%-288.17%-566.27%-7681.58%
FCF Margin
-74.63%-278.72%-448.24%-349.38%1000.63%-4060.88%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
----1.39-
PS Ratio
1.099.8811.617.9713.87643.15